Paris, France

Jérôme Meneyrol

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 5.8

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2013-2018

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jerome Meneyrol: Innovator in Anti-Thrombotic Compounds

Introduction

Jerome Meneyrol is a notable inventor based in Paris, France. He has made significant contributions to the field of pharmacology, particularly in the development of anti-thrombotic agents. His work focuses on innovative compounds that have the potential to improve therapeutic outcomes for patients with cardiovascular disorders.

Latest Patents

Meneyrol holds a patent for "Chlorothiophene-amides as inhibitors of coagulation factors Xa and thrombin." This invention relates to compounds that exhibit strong anti-thrombotic effects, making them suitable for the therapy and prophylaxis of thromboembolic diseases and restenoses. The compounds are reversible inhibitors of the blood clotting enzymes factor Xa and thrombin, which are crucial in managing conditions where undesired activity of these factors is present.

Career Highlights

Jerome Meneyrol is associated with Sanofi, a leading global healthcare company. His work at Sanofi has allowed him to focus on the development of pharmacologically active compounds that can significantly impact patient care. With a patent portfolio that includes one patent, Meneyrol continues to contribute to advancements in medical science.

Collaborations

Meneyrol has collaborated with notable colleagues such as Markus Follmann and Volkmar Wehner. These collaborations have likely enhanced the research and development processes, leading to innovative solutions in the field of anti-thrombotic therapies.

Conclusion

Jerome Meneyrol's contributions to the field of pharmacology, particularly through his patented work on anti-thrombotic compounds, highlight his role as an innovator in healthcare. His ongoing efforts at Sanofi and collaborations with esteemed colleagues further emphasize the importance of innovation in addressing cardiovascular disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…